Employees: 2,297
Size Jiang Xi Sanxin Medtec (300453.SZ) is a China Health Care company (Medical Specialties) with a market value of $744M, the 2749th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.67 on 18 Nov 2026.
Performance Over six months the shares fell 3.0%, against -16.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +10.0%); the operating margin is 18.4% (peer median 13.1%).
Valuation It trades at 16.2× forward earnings against a peer median of 19.9× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.6 points above its cost of capital (5.9% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.78B | CN¥1.63B | CN¥1.49B | CN¥1.29B | CN¥1.33B |
| Revenue growth | — | +9% | +15% | -3% | — |
| Gross profit | CN¥712M | CN¥541M | CN¥489M | CN¥421M | CN¥420M |
| EBITDA | n/a | CN¥418M | CN¥356M | CN¥304M | CN¥275M |
| Net income | CN¥290M | CN¥265M | CN¥227M | CN¥207M | CN¥185M |
| Free cash flow | CN¥174M | CN¥231M | CN¥181M | CN¥58.7M | CN¥195M |
| Capital expenditure | CN¥253M | CN¥242M | CN¥218M | CN¥287M | CN¥211M |
| Total debt | CN¥931M | CN¥394M | CN¥354M | CN¥343M | CN¥282M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300453.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | -8.5% | 6th highest of 21 |
| 6-month return | -3.0% | -16.3% | 8th highest of 21 |
| Distance from 52-week high | -10.3% | -39.8% | 5th highest of 21 |
| Revenue growth (TTM) | +12.1% | +10.0% | 11th highest of 21 |
| Operating margin | 18.4% | 13.1% | 7th highest of 21 |
| Forward P/E | 16.2× | 19.9× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -1.9% | 7.9% | 5th least demanding of 14 |
| Growth delivered (Del g) | +11.8% | +15.5% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | -13.7 pp | -9.8 pp | 6th least demanding of 14 |
| ROIC minus cost of capital | +13.6 pp | -0.3 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 14.5× | -9.5% | +2.9% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $700M | -25% | +35% | 21% | 15.9× | -3.3% | +23.5% |